1. The peptide ergot alkaloids (ergopeptines) are distinguished from other ergot subgroups by a specific structural feature at the C-8 position of the lysergic acid backbone. Which of the following correctly identifies that feature and explains its pharmacological significance?
A) A single hydroxyl group at C-8 that hydrogen-bonds directly to adrenergic receptor extracellular loops, conferring the high alpha-1 AR affinity that distinguishes ergopeptines from clavine alkaloids
B) A linear tripeptide chain at C-8 that remains open and flexible, allowing ergopeptines to adopt multiple conformations and bind promiscuously to adrenergic, dopaminergic, and serotonergic receptors without subtype selectivity
C) A tripeptide moiety at C-8 that cyclizes to form a bicyclic ring structure called the cyclol, which is the defining structural feature of the ergopeptine subgroup and the primary determinant of receptor subtype selectivity differences across individual ergopeptine alkaloids
D) A diketopiperazine ring at C-8 formed by condensation of two amino acids, which locks the ergoline scaffold into a planar conformation that prevents alpha-2 adrenergic receptor binding while preserving 5-HT1B agonism
E) A single lysergic acid amide substituent at C-8 identical to that found in LSD, which confers the serotonergic receptor promiscuity shared by all members of the ergopeptine subgroup
ANSWER: C
Rationale:
This question asked you to identify the defining structural feature of the ergopeptine subgroup and its pharmacological relevance. Option C is correct. The peptide ergot alkaloids — ergopeptines — are defined by a tripeptide moiety attached at the C-8 carboxyl position of the lysergic acid backbone. This tripeptide undergoes cyclization to form a bicyclic ring structure called the cyclol, which is unique to the ergopeptine subgroup. The specific amino acid composition of the cyclol varies across individual ergopeptines — it differs between ergotamine, ergocristine, ergocornine, and ergocryptine — and this variation is the primary structural basis for the differences in receptor subtype selectivity seen across the ergopeptine series. Semisynthetic modifications of the tripeptide substituent are what produce the dramatically different pharmacological profiles of bromocriptine (high D2 selectivity), cabergoline (very high D2 selectivity), and methysergide (5-HT2A/2C antagonism) compared to the natural ergopeptines.
Option A: Option A is incorrect. A hydroxyl group at C-8 is not the defining feature of ergopeptines; the defining feature is the tripeptide cyclol, and adrenergic receptor affinity is determined by the overall three-dimensional shape of the ergoline-cyclol complex, not by a single hydrogen-bonding substituent.
Option B: Option B is incorrect. The tripeptide at C-8 does not remain open and linear; it cyclizes to form the bicyclic cyclol ring, and this cyclization is precisely what introduces structural rigidity that enforces receptor subtype selectivity rather than promoting promiscuous non-selective binding.
Option D: Option D is incorrect. A diketopiperazine ring formed from two amino acids is not the structure at C-8 in ergopeptines; the cyclol is a bicyclic ring derived from three amino acid residues (proline and two others), not two, and the described effect on alpha-2 AR binding does not reflect the established receptor pharmacology of the ergopeptine class.
Option E: Option E is incorrect. The lysergic acid amide substituent is the defining feature of the lysergic acid amide subgroup — which includes ergine and LSD — not the ergopeptine subgroup; the ergopeptines are defined by the tripeptide cyclol at C-8, not a simple amide, and LSD's serotonergic promiscuity reflects its own pharmacophore rather than a property shared with the ergopeptine class.
2. Alpha-2 adrenergic receptors (alpha-2 ARs) are located at two anatomically and functionally distinct sites relevant to ergot alkaloid pharmacology. Which of the following correctly distinguishes the signaling and functional consequences of presynaptic versus postsynaptic alpha-2 AR activation by ergot alkaloids?
A) Presynaptic alpha-2 ARs on sympathetic nerve terminals are autoreceptors coupled to Gi protein; ergot alkaloid activation inhibits norepinephrine release via adenylyl cyclase suppression, providing negative feedback that partially attenuates the vasoconstrictive response. Postsynaptic alpha-2 ARs on vascular smooth muscle also contribute contractile drive in some vascular beds, adding to the vasoconstrictive effect of concurrent alpha-1 AR activation.
B) Presynaptic alpha-2 ARs are coupled to Gq protein and trigger vesicular norepinephrine exocytosis when activated by ergot alkaloids, amplifying sympathetic vasoconstriction. Postsynaptic alpha-2 ARs are coupled to Gi protein and mediate smooth muscle relaxation, so the net vascular effect of alpha-2 AR activation by ergots is determined by which population predominates.
C) Presynaptic and postsynaptic alpha-2 ARs are functionally identical — both are coupled to Gi protein and both produce smooth muscle relaxation when activated. Ergot alkaloids therefore produce net vasodilation through alpha-2 AR activation, with vasoconstriction arising exclusively from alpha-1 AR and 5-HT2A receptor activation.
D) Presynaptic alpha-2 ARs are Gs-coupled and increase cAMP in the nerve terminal, enhancing calcium-dependent exocytosis of norepinephrine; ergot alkaloid activation of these receptors amplifies sympathetic tone and intensifies vasoconstriction beyond what direct postsynaptic receptor activation produces alone.
E) Alpha-2 ARs in the ergot alkaloid pharmacology context are exclusively located postsynaptically on arterial smooth muscle; there are no functionally significant presynaptic alpha-2 autoreceptors in the vascular beds targeted by ergot alkaloids, so the autoreceptor concept does not apply to ergot-induced vasoconstriction.
ANSWER: A
Rationale:
This question asked you to distinguish the signaling and functional roles of presynaptic versus postsynaptic alpha-2 adrenergic receptors in ergot alkaloid pharmacology. Option A is correct. Presynaptic alpha-2 ARs located on sympathetic nerve terminals function as autoreceptors. They are coupled to Gi protein; activation inhibits adenylyl cyclase, reduces intracellular cAMP, and suppresses calcium-dependent norepinephrine exocytosis from the terminal. When ergot alkaloids activate these presynaptic autoreceptors, they reduce endogenous norepinephrine release, creating a negative feedback mechanism that partially attenuates the overall vasoconstrictive response — a paradoxical self-limiting feature of some natural ergopeptines. Postsynaptic alpha-2 ARs on vascular smooth muscle cells, by contrast, contribute direct contractile drive in some vascular beds when activated, adding to the vasoconstriction already produced by concurrent alpha-1 AR activation. DHE's enhanced potency at postsynaptic venous alpha-2 ARs relative to ergotamine accounts substantially for its greater venoconstriction.
Option B: Option B is incorrect. The coupling assignments are inverted. Presynaptic alpha-2 ARs are Gi-coupled and inhibit norepinephrine release — they do not trigger exocytosis. Postsynaptic alpha-2 ARs also couple through Gi but produce smooth muscle contraction in relevant vascular beds through downstream calcium-mobilizing pathways, not relaxation.
Option C: Option C is incorrect. While both presynaptic and postsynaptic alpha-2 ARs couple to Gi protein, their functional outputs differ by anatomical location: presynaptic activation inhibits neurotransmitter release, while postsynaptic activation in some vascular beds contributes to smooth muscle contraction. Alpha-2 AR activation by ergots does not produce net vasodilation.
Option D: Option D is incorrect. Presynaptic alpha-2 ARs are Gi-coupled, not Gs-coupled; Gi activation reduces cAMP and inhibits exocytosis rather than enhancing it. The described mechanism — Gs/increased cAMP/enhanced exocytosis — is the signaling consequence of presynaptic beta-adrenergic receptor activation, not alpha-2 AR activation.
Option E: Option E is incorrect. Functionally significant presynaptic alpha-2 autoreceptors are well established in the sympathetic vasomotor neurons supplying peripheral resistance vessels, and their activation by ergot alkaloids is a documented mechanism that attenuates the magnitude of ergot-induced vasoconstriction in some vascular beds.
3. Ergot alkaloids interact with both 5-HT1B and 5-HT2A serotonin receptor subtypes on vascular smooth muscle. Which of the following correctly distinguishes the G protein coupling, intrinsic efficacy, and vascular distribution emphasis of these two receptor subtypes as they relate to ergot alkaloid pharmacology?
A) 5-HT1B receptors are Gq-coupled and act as full agonist targets for ergotamine on cranial arterial smooth muscle; 5-HT2A receptors are Gi-coupled and act as partial agonist targets on peripheral venous smooth muscle, explaining why ergotamine produces cranial arterial constriction but peripheral venous dilation
B) 5-HT1B and 5-HT2A receptors are both Gq-coupled on vascular smooth muscle; the distinction between them is solely one of receptor density, with 5-HT1B predominating in peripheral arteries and 5-HT2A predominating in cranial arteries, which accounts for the peripheral rather than cranial selectivity of ergotamine
C) 5-HT1B receptors are coupled to Gs protein and increase cAMP in cranial arterial smooth muscle, producing relaxation of intracranial vessels that relieves migraine; 5-HT2A receptors are Gq-coupled and produce peripheral vasoconstriction, so the therapeutic and toxic effects of ergotamine reflect these two opposing receptor mechanisms operating in distinct vascular compartments
D) Both 5-HT1B and 5-HT2A receptors are Gi-coupled on all vascular smooth muscle; the functional distinction between them is determined entirely by receptor internalization kinetics rather than G protein coupling, with 5-HT1B internalizing faster and therefore producing shorter-duration vasoconstriction than 5-HT2A
E) 5-HT1B receptors are Gi-coupled and expressed at high density on cranial arterial smooth muscle including dural and pial arteries, where ergot alkaloids act as agonists to produce vasoconstriction; 5-HT2A receptors are Gq-coupled and distributed across both cranial and peripheral vascular smooth muscle, where ergot alkaloids act as partial agonists to produce an independent contractile drive through the PLC/IP3/calcium cascade
ANSWER: E
Rationale:
This question asked you to precisely distinguish 5-HT1B and 5-HT2A receptor coupling, efficacy characterization, and vascular distribution in the context of ergot alkaloid pharmacology. Option E is correct. 5-HT1B receptors are negatively coupled through Gi protein, which inhibits adenylyl cyclase and reduces cAMP; their activation on vascular smooth muscle produces vasoconstriction through downstream calcium-mobilizing pathways. These receptors are expressed at particularly high density on cranial arterial smooth muscle — notably the dural and pial arteries implicated in migraine — and ergot alkaloids act as agonists at this subtype. 5-HT2A receptors are Gq-coupled and activate phospholipase C, generating IP3-mediated calcium release from the sarcoplasmic reticulum and producing smooth muscle contraction via MLCK. Ergot alkaloids act as partial agonists at 5-HT2A receptors, generating a contractile drive independent of but additive to that produced by alpha-1 AR and 5-HT1B activation. 5-HT2A receptors are distributed across both cranial and peripheral vascular beds, which is one reason ergot alkaloids are less cranioselective than triptans.
Option A: Option A is incorrect. The coupling assignments are reversed: 5-HT1B receptors are Gi-coupled, not Gq-coupled, and 5-HT2A receptors are Gq-coupled, not Gi-coupled. Additionally, ergot alkaloids do not produce peripheral venous dilation through 5-HT2A partial agonism; 5-HT2A activation contributes to contraction, not relaxation.
Option B: Option B is incorrect. 5-HT1B and 5-HT2A receptors are not both Gq-coupled; their G protein coupling is fundamentally different, and their vascular distribution emphasis — high 5-HT1B density in cranial arteries, broader 5-HT2A distribution — is the opposite of what this option describes.
Option C: Option C is incorrect. 5-HT1B receptors are Gi-coupled, not Gs-coupled; Gi inhibits adenylyl cyclase and reduces cAMP rather than increasing it. 5-HT1B agonism produces vasoconstriction, not relaxation, and the therapeutic antimigraine effect of ergotamine reflects cranial arterial constriction rather than vasodilation.
Option D: Option D is incorrect. 5-HT1B and 5-HT2A receptors are not both Gi-coupled; this is a fundamental error in receptor pharmacology. 5-HT2A is Gq-coupled, and the functional distinction between these subtypes is rooted in their G protein coupling and downstream signaling, not solely in receptor internalization kinetics.
4. Dihydroergotamine (DHE) exerts its antimigraine effect through multiple concurrent mechanisms beyond simple cranial arterial vasoconstriction. Which of the following most completely and accurately describes DHE's pharmacological actions relevant to migraine relief?
A) DHE produces antimigraine efficacy exclusively through potent 5-HT1B agonism on cranial arterial smooth muscle; its enhanced safety profile relative to ergotamine reflects a complete absence of alpha-adrenergic and 5-HT2A receptor activity following C-9/C-10 hydrogenation
B) DHE produces cranioselective arterial vasoconstriction via 5-HT1B agonism, substantially greater venoconstriction than ergotamine via enhanced postsynaptic alpha-2 AR activity that reduces venous capacitance and increases venous return, inhibition of CGRP release from trigeminal nerve terminals via 5-HT1D agonism, and reduction of plasma extravasation from dural vessels — four concurrent mechanisms that together account for its antimigraine efficacy
C) DHE's antimigraine efficacy is mediated entirely through dopamine D2 receptor agonism in the trigeminal nucleus caudalis of the brainstem, suppressing central pain amplification; its peripheral vascular effects are pharmacologically negligible at therapeutic doses and do not contribute to headache relief
D) DHE produces antimigraine efficacy through selective 5-HT2A antagonism on meningeal vessels, blocking serotonin-induced neurogenic inflammation; the venoconstriction attributed to DHE in older literature reflects an artifact of suprapharmacological dosing in animal models rather than a clinically relevant mechanism
E) DHE and ergotamine have identical antimigraine mechanisms; the clinical preference for DHE reflects only its longer plasma half-life and once-daily dosing convenience rather than any pharmacodynamic distinction at the receptor level
ANSWER: B
Rationale:
This question asked you to identify the full set of pharmacological mechanisms contributing to DHE's antimigraine efficacy. Option B is correct. DHE exerts antimigraine effects through four concurrent mechanisms. First, 5-HT1B agonism on cranial arterial smooth muscle — particularly dural and pial arteries — produces vasoconstriction of distended meningeal vessels. Second, enhanced postsynaptic alpha-2 adrenergic receptor activity in venous smooth muscle produces substantially greater venoconstriction than ergotamine; this reduces venous capacitance, increases venous return, and reflexively reduces sympathetic outflow via baroreceptor activation. Third, 5-HT1D agonism at peripheral trigeminal nerve terminals inhibits release of calcitonin gene-related peptide (CGRP) and other vasoactive neuropeptides, suppressing the neurogenic inflammatory component of migraine. Fourth, DHE reduces plasma extravasation from dural vessels, an anti-inflammatory mechanism that contributes to meningeal pain relief. These four mechanisms operate simultaneously and complement each other, which accounts for DHE's efficacy in patients who do not respond to triptans alone.
Option A: Option A is incorrect. DHE retains meaningful alpha-adrenergic and 5-HT2A receptor activity; C-9/C-10 hydrogenation reduces arterial vasoconstrictive potency relative to ergotamine but does not eliminate non-serotonergic receptor activity. Attributing DHE's entire mechanism to 5-HT1B agonism alone ignores its well-characterized venous, neurogenic, and anti-inflammatory mechanisms.
Option C: Option C is incorrect. DHE does not produce antimigraine efficacy primarily through D2 receptor agonism in the trigeminal nucleus caudalis; this description inverts the pharmacological hierarchy. DHE's peripheral vascular and neurogenic mechanisms are well established and clinically relevant at therapeutic doses.
Option D: Option D is incorrect. DHE is not a 5-HT2A antagonist; it acts as a partial agonist at 5-HT2A receptors, contributing vasoconstriction. DHE-induced venoconstriction is a genuine pharmacodynamic property at therapeutic doses established in human pharmacological studies, not an artifact of animal suprapharmacological dosing.
Option E: Option E is incorrect. DHE and ergotamine are pharmacodynamically distinct beyond their kinetic profiles; DHE's enhanced venous activity relative to ergotamine, its different arterial-to-venous potency ratio, and its slightly different receptor selectivity profile represent genuine pharmacodynamic differences, not merely pharmacokinetic advantages.
5. The uterotonic ergot alkaloids used clinically differ from the vasoactive ergopeptines in their structural substituent at C-8 and in their clinical availability by region. Which of the following correctly describes the structural and nomenclature distinctions between ergonovine and methylergonovine?
A) Ergonovine and methylergonovine are identical compounds; "ergonovine" is the United States Pharmacopeia name while "methylergonovine" is the International Nonproprietary Name used outside the United States, and both refer to the same molecular entity with a tripeptide cyclol at C-8
B) Ergonovine carries a tripeptide cyclol substituent at C-8 identical to ergotamine, while methylergonovine carries a simple hydroxypropyl amide; this structural difference accounts for ergonovine's greater vasoconstrictive potency and methylergonovine's uterine selectivity
C) Methylergonovine is the natural alkaloid extracted directly from Claviceps purpurea; ergonovine is the semisynthetic N-methyl derivative produced by chemical modification of methylergonovine, and the prefix "ergo-" in ergonovine denotes this semisynthetic origin
D) Both ergonovine and methylergonovine carry simple amide substituents at C-8 rather than the tripeptide cyclol of the vasoactive ergopeptines; ergonovine (known as ergometrine outside North America) carries a 1-amino-2-propanol amide, while methylergonovine (Methergine in the United States) carries a d-lysergic acid methylamide moiety — structural differences that confer greater water solubility and more rapid onset than ergotamine
E) Ergonovine and methylergonovine are distinguished solely by their route of administration: ergonovine is formulated exclusively for intravenous use while methylergonovine is formulated for intramuscular use only, and no structural difference at C-8 exists between the two compounds
ANSWER: D
Rationale:
This question asked you to identify the structural and nomenclature distinctions between ergonovine and methylergonovine. Option D is correct. Both ergonovine and methylergonovine differ from the vasoactive ergopeptines (ergotamine, DHE) in that they carry simple amide substituents at C-8 rather than the complex tripeptide cyclol of the ergopeptine subgroup. Ergonovine — known as ergometrine in countries outside North America — carries a 1-amino-2-propanol amide substituent. Methylergonovine — available in the United States as Methergine — carries a d-lysergic acid methylamide moiety as its active component. These simpler amide substituents confer greater water solubility, more rapid onset of action, and a somewhat reduced peripheral vasoconstrictive profile relative to ergotamine, while preserving potent uterotonic activity through alpha-adrenergic and 5-HT2A receptor activation on myometrial smooth muscle.
Option A: Option A is incorrect. Ergonovine and methylergonovine are distinct molecular entities with different C-8 substituents; they are not the same compound with different regional names, and neither carries a tripeptide cyclol at C-8.
Option B: Option B is incorrect. Ergonovine does not carry a tripeptide cyclol identical to ergotamine; both ergonovine and methylergonovine carry simple amide substituents, not tripeptide cyclols. The characterization of ergonovine as having greater vasoconstrictive potency due to a tripeptide cyclol is structurally incorrect.
Option C: Option C is incorrect. The relationship between ergonovine and methylergonovine is inverted here. Ergonovine is the naturally occurring alkaloid; methylergonovine is the semisynthetic derivative. The "methyl-" prefix in methylergonovine reflects a modification of the amide substituent, not the reverse relationship described.
Option E: Option E is incorrect. Ergonovine and methylergonovine do have distinct structural differences at C-8 as described in Option D; they are not structurally identical compounds differentiated only by formulation and route of administration.
6. The oral bioavailability of ergotamine is low and highly variable between patients — typically less than 5% — while its pharmacodynamic effects are potent and prolonged. Which pharmacokinetic mechanism primarily accounts for this low and variable bioavailability, and what is the clinical consequence of co-administering a potent inhibitor of this pathway?
A) Ergotamine undergoes extensive renal tubular secretion after absorption, with urinary excretion removing more than 90% of absorbed drug before systemic distribution can occur; CYP3A4 inhibitors reduce renal tubular secretion by competing for the same organic anion transporter, markedly prolonging the elimination half-life but not significantly raising peak plasma concentrations
B) Ergotamine has extremely low aqueous solubility and relies on bile salt micelle formation for intestinal absorption; CYP3A4 inhibitors displace ergotamine from bile salt micelles, paradoxically reducing absorption and lowering plasma concentrations rather than raising them
C) Ergotamine undergoes extensive first-pass hepatic metabolism by CYP3A4, which is the primary mechanism of its low and variable oral bioavailability; co-administration of potent CYP3A4 inhibitors — including macrolide antibiotics, azole antifungals, and HIV protease inhibitors — markedly reduces first-pass clearance, dramatically elevating systemic plasma ergotamine concentrations and converting therapeutic doses into toxic exposures capable of producing multi-vascular vasospasm
D) Ergotamine is a P-glycoprotein substrate and is actively effluxed back into the intestinal lumen during absorption; CYP3A4 inhibitors also inhibit intestinal P-glycoprotein, so co-administration raises ergotamine bioavailability modestly but the increase is clinically insignificant because P-glycoprotein efflux — not hepatic metabolism — is the dominant bioavailability-limiting mechanism
E) Ergotamine's low oral bioavailability reflects its conversion by intestinal flora to pharmacologically inactive iso-ergot metabolites before absorption; CYP3A4 inhibitors do not alter this presystemic conversion and therefore do not significantly change ergotamine's systemic exposure or risk of vasospasm
ANSWER: C
Rationale:
This question asked you to identify the primary mechanism of ergotamine's low oral bioavailability and the clinical consequence of CYP3A4 inhibitor co-administration. Option C is correct. Ergotamine undergoes extensive first-pass hepatic metabolism mediated predominantly by the cytochrome P450 isoform CYP3A4. This extensive presystemic extraction is the primary reason oral bioavailability is below 5% and varies substantially between patients — differences in CYP3A4 expression, which is regulated by genetic polymorphisms and inducible by several drugs, explain much of the inter-patient variability. When potent CYP3A4 inhibitors are co-administered — including macrolide antibiotics such as clarithromycin and erythromycin, azole antifungals such as itraconazole and ketoconazole, and HIV protease inhibitors such as ritonavir — first-pass clearance is markedly reduced. The result is dramatically elevated systemic ergotamine plasma concentrations from the same oral dose, which drives multi-receptor activation across peripheral vascular beds and can produce life-threatening vasospasm. This interaction is listed as a contraindication to ergotamine in its prescribing information.
Option A: Option A is incorrect. Ergotamine is not eliminated primarily by renal tubular secretion; its primary elimination pathway is hepatic CYP3A4 metabolism with biliary excretion of metabolites. CYP3A4 inhibitors act on hepatic metabolism, not on renal organic anion transporters.
Option B: Option B is incorrect. While ergotamine's lipophilicity and absorption characteristics are relevant to its bioavailability, the primary mechanism of low and variable bioavailability is hepatic first-pass CYP3A4 metabolism, not bile salt micelle displacement. CYP3A4 inhibitors raise ergotamine plasma concentrations by reducing hepatic metabolism, not by altering absorption through micelle effects.
Option D: Option D is incorrect. While P-glycoprotein efflux does contribute to the low bioavailability of some lipophilic drugs including some ergot alkaloids, the dominant mechanism for ergotamine's first-pass extraction is CYP3A4 hepatic metabolism; the clinically dangerous drug interaction is mediated through CYP3A4 inhibition rather than P-glycoprotein inhibition alone.
Option E: Option E is incorrect. Ergotamine's low oral bioavailability is not attributed to intestinal flora-mediated conversion to iso-ergot metabolites; the established pharmacokinetic mechanism is hepatic CYP3A4 first-pass metabolism, and CYP3A4 inhibitors are well-documented as raising systemic ergotamine exposure and precipitating vasospasm.
7. Cabergoline is a semisynthetic dopaminergic ergot derivative used in hyperprolactinemia and Parkinson's disease, but its use in Parkinson's disease has declined due to a serious adverse effect not shared by bromocriptine at therapeutic doses. Which of the following correctly identifies this adverse effect and its pharmacological mechanism?
A) Cardiac valvulopathy — fibrotic thickening of heart valves producing regurgitation — caused by 5-HT2B receptor agonism at cardiac valve fibroblasts; cabergoline activates 5-HT2B receptors at the higher doses used in Parkinson's disease, stimulating fibroblast proliferation and collagen deposition in valve leaflets, while bromocriptine does not share this liability at therapeutic doses because it lacks meaningful 5-HT2B agonist activity
B) Hypertensive crisis — caused by cabergoline's exceptionally potent alpha-1 adrenergic agonism that exceeds that of ergotamine; at Parkinson's disease doses, systemic alpha-1 AR activation produces sustained severe hypertension not seen with bromocriptine, which has alpha-adrenergic antagonist rather than agonist activity at therapeutic doses
C) Medication overuse headache — caused by cabergoline's high-affinity 5-HT1B agonism that produces cranial vasoconstriction and central trigeminal sensitization with chronic use; the higher doses used in Parkinson's disease produce a frequency and severity of MOH not seen with bromocriptine, which has lower 5-HT1B affinity
D) Retroperitoneal fibrosis — caused by cabergoline's potent 5-HT2A partial agonism at fibroblasts surrounding the aorta and inferior vena cava; cabergoline produces this complication at all therapeutic doses including those used for hyperprolactinemia, whereas bromocriptine's lower 5-HT2A affinity confers protection against retroperitoneal fibrosis even at equivalent D2 receptor occupancy
E) Acute psychosis — caused by cabergoline's exceptionally long plasma half-life (up to 65-68 hours) producing sustained mesolimbic D2 receptor hyperstimulation at Parkinson's disease doses; bromocriptine's shorter half-life allows D2 receptor resensitization between doses, preventing the dopaminergic psychosis that cabergoline's continuous receptor occupancy produces
ANSWER: A
Rationale:
This question asked you to identify the serious adverse effect that distinguishes cabergoline from bromocriptine in Parkinson's disease treatment and its pharmacological mechanism. Option A is correct. Cabergoline is associated with cardiac valvulopathy — fibrotic thickening of heart valve leaflets producing regurgitant valvular disease, most commonly affecting the tricuspid and mitral valves. The mechanistic basis is agonism at 5-HT2B receptors on cardiac valve interstitial fibroblasts. 5-HT2B receptor activation through Gq/PLC/IP3 signaling stimulates fibroblast proliferation and collagen deposition, causing the progressive fibrous thickening of valve leaflets. Cabergoline activates 5-HT2B receptors at the higher doses required for Parkinson's disease treatment, where sustained D2 agonism is needed to provide symptomatic motor benefit. Bromocriptine does not share this liability at therapeutic doses because it does not possess meaningful 5-HT2B agonist activity. This mechanism — 5-HT2B-mediated cardiac fibrosis — is also the basis for the cardiac toxicity associated with fenfluramine (withdrawn for this reason) and high-dose ergotamine, and explains why cabergoline has been largely replaced by non-ergot dopamine agonists (pramipexole, ropinirole) for Parkinson's disease management.
Option B: Option B is incorrect. Cabergoline does not produce hypertensive crisis through alpha-1 adrenergic agonism; it is primarily a dopamine D2 agonist and does not have the potent arterial vasoconstrictive alpha-1 AR activity attributed to it here. Bromocriptine has alpha-adrenergic antagonist properties at therapeutic doses, which is correctly noted, but the described hypertensive crisis mechanism for cabergoline is not established.
Option C: Option C is incorrect. Medication overuse headache through 5-HT1B agonism is a concern with ergotamine used for migraine, not with cabergoline used for Parkinson's disease; cabergoline is not used as an antimigraine agent and 5-HT1B affinity is not the distinguishing pharmacological feature between cabergoline and bromocriptine in the Parkinson's disease context.
Option D: Option D is incorrect. Retroperitoneal fibrosis is a complication associated with methysergide, not cabergoline; the mechanism described — 5-HT2A partial agonism at periaortic fibroblasts — is the proposed mechanism for methysergide-related fibrosis, not cabergoline-related valvulopathy.
Option E: Option E is incorrect. While cabergoline does have a long plasma half-life and dopaminergic psychosis can occur with any dopamine agonist, the defining adverse effect that has driven the clinical transition away from cabergoline in Parkinson's disease is valvulopathy through 5-HT2B agonism, not psychosis from prolonged D2 receptor occupancy.
8. Ergotamine's intrinsic efficacy at alpha-1 adrenergic receptors is approximately 40–60% of the maximum response produced by norepinephrine, a full agonist. Which of the following correctly explains how this specific intrinsic efficacy value determines the drug's behavior across tissues with different baseline sympathetic tone, and what clinical observation this property predicts?
A) An intrinsic efficacy of 40–60% means ergotamine activates alpha-1 ARs at 40–60% of the receptor occupancy achieved by norepinephrine at the same concentration; in tissues with high receptor density, ergotamine therefore produces a full maximal response because spare receptors compensate for the lower occupancy rate
B) An intrinsic efficacy of 40–60% means ergotamine requires 40–60 times the molar concentration of norepinephrine to produce equivalent alpha-1 AR activation; this relative potency difference accounts for its selective use in conditions where high sympathomimetic drive would overwhelm a lower-potency agent
C) An intrinsic efficacy of 40–60% means ergotamine activates approximately half of the total alpha-1 AR pool simultaneously at any given dose; in tissues where fewer than 50% of receptors are required for a maximal response (spare receptors), ergotamine behaves as a full agonist, explaining why its vasoconstrictive effect in resting peripheral arteries can appear pharmacologically indistinguishable from a full agonist
D) An intrinsic efficacy of 40–60% is above the threshold for full agonist behavior at all G protein-coupled receptors; ergotamine therefore cannot function as a functional antagonist under any physiological condition because its intrinsic efficacy is too high to allow competitive displacement to reduce the tissue response below baseline
E) An intrinsic efficacy of 40–60% of the maximum norepinephrine response means ergotamine, even at full receptor occupancy, cannot exceed that response ceiling; in low-sympathetic-tone tissues where endogenous norepinephrine drives little baseline activation, ergotamine acts as a net agonist up to its ceiling. In high-sympathetic-tone tissues where endogenous norepinephrine already drives responses above ergotamine's ceiling, ergotamine displaces the full agonist and reduces the tissue response — producing functional antagonism. This dual behavior is the mechanistic basis of ergotamine's tissue-dependent and dose-dependent pharmacological character.
ANSWER: E
Rationale:
This question asked you to explain how ergotamine's specific intrinsic efficacy at alpha-1 ARs determines its tissue-dependent behavior. Option E is correct. Intrinsic efficacy is the maximum response a ligand can produce when it occupies 100% of a receptor population, expressed as a fraction of the maximum response a full agonist produces. Ergotamine's intrinsic efficacy at alpha-1 ARs of approximately 40–60% means that even at full receptor occupancy, ergotamine cannot drive the tissue response above 40–60% of the maximum response norepinephrine can elicit. In a tissue where baseline sympathetic tone is low — such as a peripheral artery in a resting normotensive patient — endogenous norepinephrine drives only a small fraction of the maximum response, well below ergotamine's ceiling. In this context, ergotamine acts as a net agonist, producing its near-40–60% ceiling response and causing vasoconstriction. In a tissue where sympathetic tone is maximal — such as a mesenteric artery in hemorrhagic shock with near-maximal norepinephrine-driven vasoconstriction — the tissue is already operating near or above ergotamine's intrinsic efficacy ceiling. Ergotamine competitively displaces norepinephrine from receptors and substitutes its lower intrinsic efficacy, reducing the vasoconstriction below the level norepinephrine alone maintained. This is functional antagonism — produced not by receptor blockade but by intrinsic efficacy substitution. This dual agonist/antagonist character is the mechanistic basis of ergotamine's tissue-dependent pharmacology.
Option A: Option A is incorrect. Intrinsic efficacy is not a measure of receptor occupancy fraction; it is a measure of the maximum response achievable per receptor activated. The concept of spare receptors is related but distinct: spare receptors can allow a partial agonist with low intrinsic efficacy to produce a full tissue response if enough spare receptors exist, but this applies to very low intrinsic efficacy compounds and does not change the fundamental ceiling imposed by intrinsic efficacy when receptors are fully occupied.
Option B: Option B is incorrect. Intrinsic efficacy is not a measure of relative potency or the concentration ratio required to produce equivalent effects; relative potency is determined by binding affinity (EC50), not intrinsic efficacy. Confusing potency with efficacy conflates two independent pharmacodynamic parameters that must be kept conceptually distinct.
Option C: Option C is incorrect. Intrinsic efficacy does not refer to the fraction of receptors activated simultaneously; it refers to the signal output per occupied receptor relative to a full agonist. The spare receptor argument in Option C partially captures a real concept but misapplies it — spare receptors can amplify the response of low-efficacy agonists in some tissues, but this does not mean ergotamine "behaves as a full agonist" across all vascular beds.
Option D: Option D is incorrect. An intrinsic efficacy of 40–60% does not place ergotamine above any threshold for full agonist behavior; full agonists by definition have intrinsic efficacy of 100% of the reference maximum response, and ergotamine at 40–60% is unambiguously a partial agonist. Ergotamine demonstrably produces functional antagonism in high-tone tissues, directly contradicting the claim in Option D.
9. Methysergide, historically used for migraine prophylaxis, was withdrawn from widespread use due to a serious fibrotic complication affecting multiple anatomical compartments. Which of the following correctly identifies the complication, the receptor mechanism responsible, and the pharmacological agent within the methysergide metabolic pathway that mediates this toxicity?
A) Pulmonary arterial hypertension caused by sustained 5-HT2A antagonism in the pulmonary vasculature; chronic blockade of 5-HT2A receptors on pulmonary arterial smooth muscle upregulates receptor expression, and upon drug discontinuation, endogenous serotonin activates the upregulated receptors and precipitates irreversible pulmonary hypertension. The methysergide parent compound rather than any metabolite is responsible.
B) Hepatic fibrosis caused by 5-HT1B agonism at hepatic stellate cells; methysergide's high-affinity 5-HT1B agonism activates stellate cell Gi signaling that paradoxically promotes rather than suppresses collagen synthesis, producing progressive periportal fibrosis. The O-demethylated hepatic metabolite of methysergide has higher affinity for hepatic stellate cell 5-HT1B receptors than the parent drug.
C) Cardiac valvulopathy through the same 5-HT2B mechanism as cabergoline; methysergide's active metabolite directly agonizes cardiac valve fibroblast 5-HT2B receptors, and chronic daily use for migraine prophylaxis produces the same tricuspid and mitral valve thickening seen with cabergoline in Parkinson's disease treatment. The parent compound methysergide has no 5-HT2B activity.
D) Retroperitoneal, pleuropulmonary, and cardiac fibrosis caused by 5-HT2B receptor agonism; methylergometrine, the pharmacologically active metabolite of methysergide formed by hepatic demethylation, is a potent 5-HT2B agonist that activates fibroblasts in the retroperitoneum, pleura, and cardiac valves — driving collagen deposition and progressive fibrosis in all three compartments with chronic use
E) Renal interstitial fibrosis caused by alpha-1 AR agonism in renal cortical arterioles; sustained ergot-induced renal vasoconstriction reduces glomerular perfusion and activates pro-fibrotic TGF-beta pathways in tubular epithelial cells. Methysergide's hepatic metabolites accumulate in renal cortical tissue at concentrations much higher than in the systemic circulation.
ANSWER: D
Rationale:
This question asked you to identify the fibrotic complication of methysergide, the mediating receptor, and the responsible pharmacological agent within its metabolic pathway. Option D is correct. Chronic methysergide use is associated with fibrotic reactions in three anatomical sites: the retroperitoneum (retroperitoneal fibrosis causing ureteric obstruction and vascular compression), the pleura and lungs (pleuropulmonary fibrosis), and the cardiac endocardium and valves (valvular fibrosis). The mechanism is 5-HT2B receptor agonism at fibroblasts in these locations — the same receptor subtype responsible for cabergoline's cardiac valvulopathy. The responsible pharmacological agent is methylergometrine (also called methylergonovine), the active metabolite of methysergide formed by hepatic demethylation. Methylergometrine is a potent 5-HT2B agonist; 5-HT2B receptor activation through Gq signaling in fibroblasts drives proliferation and collagen deposition, producing the progressive fibrotic responses. This complication mandated drug holidays every six months with methysergide use to allow partial regression of early fibrotic changes, and ultimately contributed to its withdrawal from most markets in favor of safer prophylactic agents.
Option A: Option A is incorrect. Pulmonary arterial hypertension from receptor upregulation after 5-HT2A antagonism is not the established mechanism of methysergide fibrotic toxicity; the fibrotic reaction involves active agonism at 5-HT2B receptors by the methylergometrine metabolite, not a rebound phenomenon following chronic receptor blockade.
Option B: Option B is incorrect. Hepatic fibrosis from 5-HT1B agonism at hepatic stellate cells is not the established toxicity of methysergide; the fibrotic complications are retroperitoneal, pleuropulmonary, and cardiac, not primarily hepatic. 5-HT1B-mediated stellate cell collagen synthesis is not the described mechanism, and an O-demethylated hepatic metabolite with higher 5-HT1B affinity is not the pharmacological account of methysergide fibrosis.
Option C: Option C is incorrect. While methysergide does produce valvulopathy through 5-HT2B agonism by its methylergometrine metabolite, this option incorrectly states that the parent compound methysergide has no 5-HT2B activity; more importantly, it omits the retroperitoneal and pleuropulmonary components of the fibrotic syndrome that are the defining and most clinically dangerous manifestations of methysergide toxicity.
Option E: Option E is incorrect. Renal interstitial fibrosis through alpha-1 AR-mediated TGF-beta activation is not the established mechanism of methysergide fibrotic toxicity; methysergide has minimal clinically significant alpha-adrenergic activity, and renal cortical metabolite accumulation is not the pharmacokinetic basis of the fibrotic complications.
10. Ergot alkaloids, as partial agonists at G protein-coupled receptors, interact with receptor desensitization machinery differently than full agonists such as norepinephrine. Which of the following correctly describes how ergot partial agonism influences receptor internalization dynamics and what pharmacological consequence this produces?
A) Partial agonists such as ergot alkaloids bind G protein-coupled receptors but do not activate G protein-coupled receptor kinases (GRKs) or recruit beta-arrestin under any circumstances, because GRK phosphorylation requires a conformational change achievable only by full agonists; ergot alkaloids therefore produce prolonged receptor signaling without desensitization regardless of dose or duration of exposure
B) Ergot alkaloids, as partial agonists, stabilize distinct receptor conformations that differ from those stabilized by full agonists; these distinct conformations may drive GRK phosphorylation and beta-arrestin recruitment at different rates than full agonist-bound conformations — producing qualitatively different temporal patterns of desensitization and resensitization that contribute to the prolonged and variable pharmacodynamic responses seen clinically, and that underlie receptor adaptations associated with medication overuse headache with chronic ergotamine use
C) Ergot alkaloids as partial agonists bypass the GRK/beta-arrestin internalization pathway entirely and produce receptor downregulation exclusively through transcriptional suppression of receptor gene expression; this mechanism explains why ergot alkaloid pharmacodynamic effects persist for 24 hours or more after plasma clearance — receptor recovery requires de novo receptor protein synthesis rather than membrane recycling
D) Because ergot alkaloids have lower intrinsic efficacy than full agonists, they produce weaker GRK activation and therefore slower receptor internalization than full agonists; this slower internalization means ergot-occupied receptors remain at the cell surface longer and are available for re-activation by endogenous norepinephrine, amplifying rather than attenuating the vasoconstrictive response over time
E) Ergot alkaloids activate beta-arrestin pathways preferentially over G protein pathways at all receptors where they bind, a property called biased agonism that is identical across all ergot alkaloids regardless of their structural differences; this universal beta-arrestin bias explains why all ergot alkaloids produce identical receptor internalization kinetics despite their different receptor subtype selectivity profiles
ANSWER: B
Rationale:
This question asked you to describe how ergot partial agonism influences receptor desensitization machinery and what pharmacological consequence this produces. Option B is correct. G protein-coupled receptor signaling is terminated by a sequence of events: after agonist activation, G protein-coupled receptor kinases (GRKs) phosphorylate specific serine and threonine residues on the intracellular face of the activated receptor; beta-arrestin then binds to the phosphorylated receptor, sterically blocking further G protein coupling and targeting the receptor for clathrin-mediated endocytosis and internalization. Full agonists and partial agonists stabilize distinct receptor conformations that present different phosphorylation sites and beta-arrestin docking geometries to GRKs. Ergot alkaloids, by stabilizing their own distinct receptor conformational states, may drive GRK-mediated phosphorylation and beta-arrestin recruitment at rates that differ from those induced by full agonists — producing different temporal profiles of receptor desensitization, internalization, and eventual resensitization after receptor recycling. These differences in receptor trafficking kinetics contribute to the complex and prolonged pharmacodynamic responses observed with ergot alkaloids and, with chronic exposure, to the receptor-level adaptations associated with medication overuse headache. This framework — distinct receptor conformations from partial agonism producing distinct desensitization kinetics — is an extension of the concept of functional selectivity or biased agonism.
Option A: Option A is incorrect. Partial agonists do not universally fail to activate GRKs or recruit beta-arrestin; their distinct receptor conformations do engage GRK/beta-arrestin machinery, albeit at potentially different rates and stoichiometries than full agonists. The claim that ergot alkaloids produce zero receptor desensitization regardless of dose is not supported and is inconsistent with the receptor adaptations observed clinically.
Option C: Option C is incorrect. Ergot alkaloid-induced receptor downregulation is not mediated exclusively through transcriptional suppression requiring de novo receptor synthesis for recovery; receptor internalization via the GRK/beta-arrestin/clathrin pathway is the primary mechanism of receptor removal from the cell surface, and internalized receptors can be recycled to the membrane after dephosphorylation and sorting in endosomes without requiring new transcription.
Option D: Option D is incorrect. Slower GRK activation from lower intrinsic efficacy is a plausible consideration, but the conclusion that ergot-occupied receptors remaining at the surface would amplify vasoconstriction over time is incorrect; slower desensitization would maintain receptor availability for the ergot alkaloid itself rather than for endogenous norepinephrine, and the complex clinical pharmacodynamics of ergots is not fully explained by simple GRK activation rate differences.
Option E: Option E is incorrect. Biased agonism — preferential activation of beta-arrestin pathways over G protein pathways — is not a universal property identical across all ergot alkaloids. Different ergot derivatives stabilize different receptor conformational states depending on their structural features, and the degree and type of signaling bias varies across the series. Asserting identical beta-arrestin bias for all ergot alkaloids regardless of structural differences is inconsistent with the functional selectivity concept as applied to this class.
11. Historical outbreaks of ergotism from contaminated grain produced two clinically distinct syndromes. Which of the following correctly distinguishes these two syndromes by their clinical presentation and the receptor mechanism that predominantly accounts for each?
A) The vasodilatory syndrome featured warm, flushed extremities with bounding pulses caused by 5-HT1A agonism in peripheral resistance arteries; the vasoconstrictive syndrome featured cold, pulseless extremities caused by alpha-1 AR agonism. The vasodilatory syndrome predominated in summer outbreaks when high ambient temperature amplified serotonergic vasodilation.
B) The hemorrhagic syndrome featured spontaneous bleeding and coagulopathy caused by ergot alkaloid-induced platelet 5-HT2A receptor downregulation, which impaired thromboxane A2-mediated platelet aggregation; the fibrotic syndrome featured organ fibrosis caused by chronic low-level ergot exposure activating 5-HT2B receptors in connective tissue. Both syndromes occurred simultaneously in the same affected populations.
C) The gangrenous form was characterized by intense peripheral vasoconstriction leading to dry gangrene of the extremities, reflecting alpha-adrenergic and 5-HT2A receptor-mediated arterial spasm in limb vessels; the convulsive form was characterized by seizures, hallucinations, and psychiatric disturbances, reflecting central nervous system effects of ergot alkaloids, possibly through serotonergic and dopaminergic pathways in the CNS
D) Both syndromes were caused by the same receptor mechanism — 5-HT2A agonism — but the gangrenous form occurred in patients who consumed ergot-contaminated grain chronically over months, while the convulsive form occurred in patients who consumed a single large acute dose; the distinction is entirely pharmacokinetic rather than reflecting different receptor targets
E) The gangrenous form resulted from ergot alkaloid-induced vasodilation of peripheral arterioles causing arteriovenous shunting that deprived distal tissues of oxygen; the convulsive form resulted from cerebral vasoconstriction causing focal ischemia in cortical regions governing motor and sensory function. Both forms were caused by dihydroergotamine-like natural alkaloids preferentially contaminating specific grain varieties.
ANSWER: C
Rationale:
This question asked you to distinguish the two historical ergotism syndromes by clinical presentation and predominant receptor mechanism. Option C is correct. Historical ergotism produced two phenotypically distinct clinical syndromes depending on the specific alkaloid composition of the contaminated grain and the geographic and nutritional context of the affected population. The gangrenous form — historically known as St. Anthony's Fire — was characterized by intense peripheral vasoconstriction in limb arteries, producing ischemia that progressed to dry gangrene of the fingers, toes, and entire extremities. This presentation directly reflects alpha-adrenergic and 5-HT2A receptor-mediated arterial vasospasm in the peripheral vasculature, the same mechanism responsible for modern ergot toxicity in clinical use. The convulsive form was characterized by seizures, hallucinations, and a range of psychiatric disturbances including the behavioral abnormalities that have been retrospectively proposed as contributing to historical mass psychogenic episodes. The central effects are attributed to ergot alkaloid actions in the CNS through serotonergic pathways — particularly at 5-HT2 receptor subtypes in cortical and limbic circuits — and dopaminergic pathway effects. The gangrenous form was more common in France and western Europe, while the convulsive form was more common in German-speaking regions, a geographic distribution that correlated with differences in ergot alkaloid composition of the local fungal strains.
Option A: Option A is incorrect. A vasodilatory peripheral syndrome from 5-HT1A agonism is not one of the established historical ergotism syndromes; ergotism is fundamentally a vasoconstrictive and central neurotoxic disorder, and a warm-extremity vasodilatory syndrome is not recorded as a clinical ergotism presentation.
Option B: Option B is incorrect. A hemorrhagic coagulopathy syndrome from platelet 5-HT2A receptor downregulation is not one of the established historical ergotism syndromes; platelet aggregation effects of ergot alkaloids are a secondary pharmacological consideration, not the mechanism of a distinct clinical syndrome in historical outbreaks.
Option D: Option D is incorrect. The two syndromes are not pharmacokinetically distinguished by dose or duration of exposure to identical alkaloids; they are distinct clinical presentations that reflect different predominant receptor targets and appear to correlate with differences in alkaloid composition across contaminated grain sources.
Option E: Option E is incorrect. The gangrenous form resulted from vasoconstriction, not vasodilation causing arteriovenous shunting; the pathophysiology of gangrenous ergotism is ischemia from arterial spasm, not from arteriovenous shunting. Dihydroergotamine is a semisynthetic compound not found in contaminated grain.
12. Bromocriptine is a semisynthetic ergot derivative with high dopamine D2 receptor selectivity, while the natural ergopeptine ergotamine has weak and clinically insignificant D2 activity despite sharing the same ergoline backbone. Which of the following correctly explains the structural basis for this difference in D2 receptor selectivity?
A) The difference in D2 receptor selectivity between bromocriptine and ergotamine is primarily determined by modification of the tripeptide cyclol substituent at C-8; the specific amino acid composition and stereochemistry of the cyclol in bromocriptine — achieved by semisynthetic modification of the natural peptide scaffold — shifts receptor selectivity toward D2 agonism and away from the predominant alpha-adrenergic and serotonergic activities of natural ergopeptines such as ergotamine
B) Bromocriptine achieves D2 selectivity through bromination at the C-2 position of the ergoline ring, which directly contacts the D2 receptor orthosteric binding site; ergotamine lacks this bromine substituent and therefore cannot access the D2 receptor binding pocket, explaining its negligible D2 activity regardless of the peptide substituent
C) D2 receptor selectivity in bromocriptine reflects the absence of the tripeptide substituent at C-8; bromocriptine is a lysergic acid amide, not an ergopeptine, and its simple amide at C-8 allows the ergoline ring to adopt the planar conformation required for D2 receptor binding that the bulky tripeptide cyclol in ergotamine sterically prevents
D) Bromocriptine achieves D2 selectivity through hydrogenation at C-9/C-10 identical to the modification that produces DHE from ergotamine; the C-9/C-10 double bond in natural ergopeptines sterically blocks D2 receptor access, and removal of this double bond by hydrogenation is the single modification responsible for D2 selectivity across all dopaminergic ergot derivatives including bromocriptine and cabergoline
E) The difference between bromocriptine and ergotamine reflects differential expression of D2 receptor splice variants in the anterior pituitary versus peripheral tissues; both compounds have equivalent affinity for the D2-long isoform in peripheral vasculature, but bromocriptine selectively binds the D2-short isoform expressed exclusively in the anterior pituitary, producing apparent D2 selectivity that is purely a receptor expression phenomenon rather than a structural pharmacology difference
ANSWER: A
Rationale:
This question asked you to identify the structural basis for bromocriptine's D2 receptor selectivity compared to ergotamine's weak D2 activity. Option A is correct. Both ergotamine and bromocriptine are ergopeptines sharing the lysergic acid ergoline backbone and a tripeptide cyclol at C-8. The dramatic difference in their receptor selectivity profiles — ergotamine being predominantly adrenergic and serotonergic with weak D2 activity, bromocriptine being a high-affinity D2 agonist with relatively less adrenergic and serotonergic activity — is primarily attributable to differences in the amino acid composition, stereochemistry, and structural geometry of the tripeptide cyclol substituent at C-8. Semisynthetic modification of the natural peptide scaffold changes the three-dimensional shape presented to receptor binding pockets, shifting which receptor families are engaged most productively. The cyclol substituent is the dominant determinant of receptor selectivity differences across the ergopeptine series — it accounts for why natural ergopeptines (ergotamine, ergocristine, ergocryptine) have similar pharmacological profiles while semisynthetic ergopeptines (bromocriptine, cabergoline, methysergide) have dramatically different profiles from each other and from the naturals.
Option B: Option B is incorrect. While bromination at C-2 is a structural feature of bromocriptine that contributes to its pharmacophore, the primary determinant of D2 selectivity across the ergopeptine series is the peptide substituent at C-8, not the halogen at C-2 alone. The mechanistic explanation in Option B oversimplifies to a single-atom contact model that does not account for the conformational pharmacology of the ergoline-cyclol complex at D2 receptors.
Option C: Option C is incorrect. Bromocriptine is an ergopeptine — it does carry a tripeptide cyclol at C-8 — not a lysergic acid amide. The lysergic acid amides (ergine, LSD) are a distinct subgroup. Assigning bromocriptine to the lysergic acid amide subclass is a fundamental structural classification error.
Option D: Option D is incorrect. Hydrogenation at C-9/C-10 produces dihydro derivatives (DHE from ergotamine), but this modification is not the basis of D2 selectivity. Bromocriptine retains the C-9/C-10 unsaturation of natural ergopeptines; the C-9/C-10 double bond in ergotamine does not sterically block D2 access, and all dopaminergic ergot derivatives do not require C-9/C-10 hydrogenation for D2 activity.
Option E: Option E is incorrect. D2 receptor splice variant distribution does not explain the pharmacological distinction between bromocriptine and ergotamine; bromocriptine's D2 selectivity is a genuine structural pharmacology property demonstrable in cell-free binding assays using cloned D2 receptors, not a tissue-expression artifact. Both the D2-long and D2-short isoforms bind both compounds at the same orthosteric site, and the selectivity difference reflects ligand structure, not receptor isoform expression.
13. In the management of established ergot-induced peripheral vasospasm, vasodilators that act downstream of receptor activation are required for reversal. Which of the following correctly identifies the intracellular mechanisms by which nitroprusside and prostaglandin E1 (PGE1) reverse ergot-induced smooth muscle contraction, and explains why these agents succeed where receptor antagonists alone are insufficient?
A) Nitroprusside competitively antagonizes ergotamine at alpha-1 adrenergic receptors, while PGE1 competitively antagonizes ergotamine at 5-HT2A receptors; together they provide complete receptor-level blockade of both vasoconstrictive pathways. They are preferred over phentolamine because their receptor antagonism is irreversible, producing a more sustained reversal that outlasts ergotamine's prolonged pharmacodynamic effect.
B) Nitroprusside activates soluble guanylyl cyclase by releasing nitric oxide, increasing cGMP and activating protein kinase G, which phosphorylates myosin light chain phosphatase and promotes smooth muscle relaxation independent of receptor occupancy; PGE1 activates Gs-coupled prostanoid EP receptors, increasing cAMP and activating protein kinase A, which similarly phosphorylates MLCK and reduces its activity — both mechanisms acting downstream of the alpha-adrenergic and serotonergic receptors that ergot alkaloids activate
C) Nitroprusside and PGE1 both act by competitively displacing ergotamine from alpha-1 adrenergic receptors through allosteric modulation of the receptor's extracellular binding domain; their advantage over phentolamine is that they bind to a distinct allosteric site that allows displacement of partial agonists but not of catecholamine full agonists, preserving sympathetic vasoconstrictor tone while reversing the ergot component
D) Nitroprusside acts by inhibiting CYP3A4, reducing ergotamine plasma concentrations through pharmacokinetic reversal of the drug's slow dissociation from receptors; PGE1 activates prostacyclin receptors to suppress thromboxane A2 synthesis, which is the primary contractile mediator released by ergot-activated platelets in the spastic vessel wall
E) Both nitroprusside and PGE1 produce smooth muscle relaxation through second messenger pathways — cGMP and cAMP respectively — that operate entirely downstream of the receptor-ligand interaction; because ergot-induced vasospasm involves simultaneous activation of alpha-adrenergic, 5-HT1B, and 5-HT2A receptors, blocking any single receptor family leaves other contractile drives intact, whereas downstream cGMP and cAMP elevation overrides the contractile signal regardless of which receptor subtypes remain occupied by ergot alkaloid
ANSWER: E
Rationale:
This question asked you to explain the intracellular mechanisms of nitroprusside and PGE1 in ergot vasospasm reversal and why downstream vasodilators succeed where receptor antagonists alone are insufficient. Option E is correct. Nitroprusside is a nitric oxide (NO) donor; released NO activates soluble guanylyl cyclase in smooth muscle cells, generating cyclic GMP (cGMP). cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain phosphatase, activates it, and promotes dephosphorylation of myosin light chains — reducing cross-bridge cycling and producing relaxation. This entire cascade operates downstream of receptor occupancy: nitroprusside produces relaxation regardless of which receptors are occupied at the cell surface. PGE1 binds to Gs-coupled prostanoid EP receptors, activating adenylyl cyclase, raising cAMP, and activating protein kinase A (PKA). PKA phosphorylates and inactivates myosin light chain kinase (MLCK) while also promoting calcium re-uptake into the sarcoplasmic reticulum — producing smooth muscle relaxation through a cAMP-dependent pathway independent of receptor occupancy. Because ergot vasospasm simultaneously engages alpha-1 AR, alpha-2 AR postsynaptic, 5-HT1B, and 5-HT2A receptor-mediated contractile drives, blocking only the adrenergic component with phentolamine leaves the serotonergic components intact and produces only partial reversal. Downstream second messenger elevation overrides the integrated contractile signal from all simultaneously activated receptor pathways.
Option A: Option A is incorrect. Nitroprusside and PGE1 are not competitive receptor antagonists at alpha-1 AR and 5-HT2A receptors respectively; their mechanisms are entirely downstream of receptor activation through cGMP and cAMP signaling. Neither agent produces irreversible receptor blockade.
Option B: Option B is incorrect as the best answer. While its pharmacological description of nitroprusside and PGE1 mechanisms is accurate, it omits the key explanatory element — the multi-receptor basis of ergot vasospasm that makes single-receptor blockade inadequate — which is precisely the pharmacological point the question tests. Without that element, Option B fails to explain why downstream vasodilators are specifically required over receptor antagonists, making it an incomplete answer to the question asked.
Option C: Option C is incorrect. Neither nitroprusside nor PGE1 acts by allosteric modulation of alpha-1 AR to displace partial agonists; their mechanisms are entirely post-receptor, operating through second messenger systems, and the described allosteric selectivity for partial agonist displacement does not reflect established pharmacology of either agent.
Option D: Option D is incorrect. Nitroprusside does not inhibit CYP3A4; it is a vasodilator acting through the NO/cGMP pathway. PGE1 does not act primarily by suppressing thromboxane A2 synthesis through prostacyclin receptors; its vasodilatory effect in ergot vasospasm is mediated by Gs-coupled EP receptor activation raising cAMP in vascular smooth muscle.
14. In postpartum hemorrhage (PPH) management, oxytocin is first-line and methylergonovine is second-line. A clinician asks why oxytocin is preferred despite ergot alkaloids producing more intense uterine contraction in the estrogen-primed postpartum uterus. Which pharmacological explanation best justifies oxytocin's first-line status?
A) Oxytocin has a substantially longer duration of uterotonic action than methylergonovine — 6 to 8 hours per dose versus 3 to 6 hours — allowing less frequent dosing during the critical first hours of PPH management, and its longer duration is the primary pharmacological rationale for first-line preference
B) Oxytocin acts at receptors expressed exclusively on the outer myometrial layer (perimetrium), producing mechanical compression of the uterine body that directly collapses the placental bed vascular sinuses; methylergonovine acts on the inner myometrial layer (endometrium) and produces contraction that does not directly compress the subendometrial vascular network responsible for placental site bleeding
C) Oxytocin is preferred because it lacks any vasoconstrictive activity at therapeutic doses, while methylergonovine's concurrent systemic alpha-adrenergic vasoconstriction raises blood pressure and is dangerous in all postpartum patients regardless of baseline blood pressure status
D) Oxytocin acts via Gq-coupled oxytocin receptors — whose density increases dramatically at term and in the early postpartum period — to produce rhythmic, coordinated, phasic contractions that mimic physiological uterine activity and allow uteroplacental blood flow restoration between contractions; this phasic pattern effectively compresses the myometrial vasculature to control hemorrhage without the sustained tonic contraction of ergots that continuously compromises uteroplacental perfusion and carries a pressor risk that limits use in patients with elevated blood pressure
E) Oxytocin is first-line exclusively because of regulatory and cost considerations rather than pharmacological superiority; methylergonovine is pharmacologically equivalent in efficacy and safety for all postpartum patients and would be preferred based on pharmacological merit alone if cost and access were equal
ANSWER: D
Rationale:
This question asked you to justify oxytocin's first-line status in PPH management on pharmacological grounds. Option D is correct. Oxytocin acts via Gq-coupled oxytocin receptors whose expression increases dramatically at term and in the early postpartum period in response to estrogen upregulation; this receptor density increase is the physiological basis for the uterus's responsiveness to endogenous oxytocin at the onset of labor. Oxytocin produces rhythmic, coordinated, phasic contractions — frequency- and amplitude-modulated waves that compress the myometrial vasculature during the contraction phase and allow some degree of uteroplacental blood flow restoration during the relaxation intervals. This phasic pattern is effective for postpartum hemorrhage control through myometrial vascular compression while remaining less physiologically disruptive than sustained tonic contraction. Methylergonovine, in contrast, produces tonic, sustained, non-rhythmic contraction through alpha-adrenergic and 5-HT2A receptor activation, which continuously compresses the myometrial vasculature without relaxation intervals. Additionally, methylergonovine's concurrent systemic alpha-adrenergic vasoconstriction raises blood pressure and is absolutely contraindicated in patients with gestational hypertension, preeclampsia, or eclampsia — a clinically important subset of patients with PPH. Oxytocin's absence of meaningful systemic vasoconstrictive activity at therapeutic doses makes it safe in hypertensive patients and in all postpartum patients as a first choice.
Option A: Option A is incorrect. The duration of action comparison is approximately the reverse of what is stated; methylergonovine actually has a longer duration of uterotonic action (3–6 hours per IM dose) than the intravenous oxytocin infusion that must be maintained continuously. Duration is not the pharmacological rationale for oxytocin's first-line preference.
Option B: Option B is incorrect. The description of oxytocin and methylergonovine acting on distinct myometrial layers — perimetrium versus endometrium — does not reflect established uterine pharmacology; both agents act on myometrial smooth muscle throughout the uterine wall, and neither is selectively restricted to one anatomical layer.
Option C: Option C is incorrect. The statement that methylergonovine's pressor effect is dangerous in all postpartum patients regardless of blood pressure is an overstatement; in normotensive postpartum patients, the pressor response to methylergonovine is generally well-tolerated. The correct clinical rule is that it is contraindicated specifically in patients with hypertension, preeclampsia, or eclampsia, not universally dangerous.
Option E: Option E is incorrect. Oxytocin's first-line status reflects genuine pharmacological advantages — favorable contraction pattern, absence of vasoconstrictive contraindications, well-characterized safety profile — not regulatory or cost considerations. Methylergonovine is not pharmacologically equivalent in safety across all postpartum patients due to its pressor liability.
15. Clinicians managing ergot-induced vasospasm note that the quality and reversibility of the vasoconstriction differ from that produced by high-dose catecholamines acting at the same alpha-adrenergic receptors. The concept of functional selectivity — also called biased agonism — has been invoked to explain this difference. Which of the following correctly applies this concept to ergot alkaloid receptor pharmacology?
A) Functional selectivity in ergot pharmacology refers to the tissue-selective distribution of receptor subtypes across vascular beds; ergot alkaloids produce biased agonism by preferentially distributing to cranial versus peripheral vascular compartments after systemic administration, activating different receptor populations by pharmacokinetic partitioning rather than by differential receptor-level signaling
B) Functional selectivity means that different ligands at the same receptor can stabilize distinct receptor conformations that couple preferentially to different downstream pathways — G protein versus beta-arrestin — producing qualitatively different cellular responses. Ergot alkaloids stabilize receptor conformational states that differ from those stabilized by catecholamines at the same alpha-adrenergic receptors, potentially driving different ratios of G protein versus beta-arrestin signaling; this qualitative difference in intracellular signaling — not just receptor occupancy — contributes to the prolonged, refractory character of ergot vasospasm that cannot be fully explained by simple competitive receptor occupancy models
C) Functional selectivity is synonymous with receptor subtype selectivity; the term "biased agonism" in ergot pharmacology refers exclusively to ergotamine's preferential binding to alpha-1 versus alpha-2 adrenergic receptor subtypes, with "bias" describing the affinity ratio between these two subtypes rather than any differential coupling to downstream signaling pathways within a single receptor subtype
D) Functional selectivity in ergot pharmacology describes the selective activation of vascular smooth muscle receptors over cardiac receptors by ergot alkaloids; because ergot alkaloids cannot cross lipid bilayer membranes as efficiently as catecholamines, they activate only cell-surface receptors on vascular smooth muscle and cannot engage the internalized receptor pool that mediates cardiac inotropic responses
E) Functional selectivity is a theoretical concept that has not been experimentally demonstrated for ergot alkaloids at any receptor subtype; the clinical observation that ergot vasospasm behaves differently from catecholamine-induced vasoconstriction is fully explained by differences in plasma half-life and receptor binding affinity alone, without invoking differential intracellular signaling pathway engagement
ANSWER: B
Rationale:
This question asked you to correctly apply the concept of functional selectivity or biased agonism to ergot alkaloid receptor pharmacology. Option B is correct. Functional selectivity — biased agonism — is the pharmacological principle that different ligands binding to the same receptor can stabilize distinct receptor conformational states that preferentially couple to different downstream signaling pathways. In G protein-coupled receptor pharmacology, the two major downstream signaling arms are the canonical G protein pathway (activating second messengers such as cAMP, IP3, and calcium) and the beta-arrestin pathway (mediating receptor desensitization, internalization, and receptor-independent signaling). A ligand that preferentially drives G protein coupling is described as G protein-biased, while one that preferentially drives beta-arrestin recruitment is described as beta-arrestin-biased. Ergot alkaloids, as partial agonists, stabilize receptor conformational states that differ from those stabilized by catecholamines such as norepinephrine at the same alpha-adrenergic receptors. These different conformational states present different phosphorylation sites and docking geometries to GRKs and beta-arrestin, potentially driving different ratios of G protein versus beta-arrestin signaling. The consequence is that ergot alkaloid activation of alpha-adrenergic receptors produces a qualitatively different intracellular signal profile than catecholamine activation, even when the same receptor is occupied. This qualitative difference — not merely occupancy level — has been proposed to contribute to the particularly prolonged, slow-reversing, and refractory character of ergot-induced vasospasm that cannot be fully accounted for by simple receptor occupancy and competitive pharmacology alone.
Option A: Option A is incorrect. Functional selectivity and biased agonism refer to differential intracellular signaling pathway engagement at the receptor level, not to pharmacokinetic tissue partitioning. The concept is a receptor-level, ligand-conformation phenomenon, not a distribution phenomenon.
Option C: Option C is incorrect. Functional selectivity is not synonymous with receptor subtype selectivity. Receptor subtype selectivity describes which receptor among a family (alpha-1 vs. alpha-2) a drug preferentially binds. Biased agonism describes differential coupling to downstream pathways within a single receptor subtype; these are entirely different concepts that operate at different levels of pharmacological organization.
Option D: Option D is incorrect. Functional selectivity has nothing to do with membrane permeability or access to internalized receptor pools; it is a conformational pharmacology concept describing ligand-stabilized receptor states and their differential downstream signaling.
Option E: Option E is incorrect. Biased agonism and functional selectivity have been experimentally demonstrated for ergot alkaloids and other partial agonists at multiple receptor subtypes in cellular and biochemical systems; these are not merely theoretical constructs. Dismissing the concept as entirely undemonstrated contradicts an established body of receptor pharmacology research.
16. A clinical pharmacologist reviews the contraindication profile of ergot alkaloids as a class. Which of the following provides the most pharmacologically complete and accurate account of the absolute contraindications to ergotamine and DHE, with the correct mechanistic justification for each?
A) Ergotamine and DHE are contraindicated only in patients with active coronary artery disease; all other listed contraindications — peripheral vascular disease, hypertension, concurrent CYP3A4 inhibitor use — are relative contraindications that require dose reduction rather than absolute avoidance, and the absolute contraindication to coronary artery disease is based on 5-HT1B receptor-mediated coronary spasm rather than alpha-adrenergic activation
B) The only pharmacologically justified absolute contraindication to ergotamine and DHE is concurrent use of potent CYP3A4 inhibitors; all vascular disease contraindications are precautionary labels rather than mechanistically supported, because clinical trials in patients with peripheral vascular disease have not demonstrated higher rates of vasospasm than in vascular disease-free controls at recommended doses
C) Ergotamine and DHE are absolutely contraindicated in patients with coronary artery disease, peripheral vascular disease, and cerebrovascular disease — because their combined alpha-adrenergic and serotonergic vasoconstriction is not vascular-bed selective and will cause vasospasm in already-compromised vessels — in pregnancy beyond the immediate postpartum period — because estrogen-upregulated myometrial 5-HT2A receptors make the pregnant uterus exquisitely sensitive to tonic ergot contraction — and during concurrent use of potent CYP3A4 inhibitors — because CYP3A4 inhibition elevates ergot plasma concentrations into the vasospasm-toxic range. Methylergonovine carries the additional absolute contraindication of hypertension and preeclampsia due to its alpha-adrenergic pressor effect.
D) Ergotamine and DHE are contraindicated in patients with peripheral vascular disease and in patients taking monoamine oxidase inhibitors (MAOIs); the MAOI interaction produces a serotonin syndrome when combined with the serotonergic agonism of ergot alkaloids, while all other contraindications listed in prescribing information reflect excessive caution from case reports rather than established pharmacological mechanisms
E) The primary absolute contraindication to ergotamine and DHE is concurrent use of any serotonergic drug, because ergot 5-HT1B/1D agonism combined with SSRI-induced serotonin accumulation invariably produces serotonin syndrome; vascular disease contraindications are secondary and apply only when the patient's vascular disease is symptomatic at rest, not when it is well-controlled with medical therapy
ANSWER: C
Rationale:
This question asked you to provide the pharmacologically complete account of absolute contraindications to ergotamine and DHE with mechanistic justification. Option C is correct. The absolute contraindication profile of ergotamine and DHE follows directly from the mechanisms established in this module. Coronary artery disease, peripheral vascular disease, and cerebrovascular disease are absolute contraindications because ergot alkaloids lack true vascular bed selectivity — their combined activation of alpha-1 AR, alpha-2 AR postsynaptic, 5-HT1B, and 5-HT2A receptors produces vasoconstriction not only in cranial vessels but in coronary, digital, mesenteric, and cerebral vessels. In patients with pre-existing fixed atherosclerotic disease or already-compromised vasculature, the additional vasospastic stimulus can precipitate myocardial infarction, limb ischemia, or stroke. Pregnancy beyond the immediate postpartum period is an absolute contraindication because estrogen-driven upregulation of myometrial 5-HT2A receptors makes the pregnant uterus exquisitely sensitive to ergot-induced tonic contraction, creating a risk of tetanic uterine contraction, placental vascular compression, and fetal hypoxia or death. Concurrent potent CYP3A4 inhibitor use is an absolute contraindication because CYP3A4 inhibition eliminates ergot alkaloid first-pass hepatic extraction, converting therapeutic doses into toxic plasma exposures that drive multi-vascular vasospasm. Methylergonovine carries the additional absolute contraindication of hypertension and preeclampsia due to its alpha-adrenergic systemic pressor effect.
Option A: Option A is incorrect. Peripheral vascular disease, pregnancy, and CYP3A4 inhibitor co-administration are established absolute contraindications to ergot alkaloids, not merely relative ones requiring dose reduction; and the stated mechanism of the coronary contraindication — 5-HT1B rather than alpha-adrenergic — is incomplete, as both receptor mechanisms contribute to coronary vasospasm.
Option B: Option B is incorrect. The vascular disease contraindications to ergotamine and DHE are mechanistically supported by the multi-receptor non-selective vasoconstrictive pharmacology of these agents; dismissing them as precautionary labels without mechanistic basis is inconsistent with established ergot pharmacology and prescribing information.
Option D: Option D is incorrect. MAOIs are not the primary or pharmacologically dominant contraindication to ergot alkaloids; the MAOI-ergot serotonin syndrome risk is a drug interaction concern but does not represent the primary class of absolute contraindications, which are the vascular disease and pregnancy contraindications arising from the drugs' fundamental vasoconstrictive and uterotonic mechanisms.
Option E: Option E is incorrect. Concurrent SSRI use does not invariably produce serotonin syndrome with ergot alkaloids; serotonin syndrome from this combination is rare and not established as an absolute contraindication. Vascular disease contraindications are not secondary or conditional on whether disease is symptomatic at rest; even well-controlled coronary artery disease represents an absolute contraindication to ergotamine and DHE.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.